NSE: AJANTPHARM | BSE: 532331

Expensive Performer

Download real time

2654.25 27.90 (1.06%)

29.37% Gain from 52W Low

177 NSE+BSE Volume

NSE 21 Mar, 2025 9:07 AM (IST)

33,154.8

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

31 Jul 2021

2654.25

1.06%

Ajanta Pharma (BUY): Strong earnings growth; reiterate BUY

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Q1 PAT robust at Rs 1.7bn, up 17% YoY. Sales grew 12% YoY while EBITDA declined 2%

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

30 Jul 2021

2654.25

1.06%

DF, US, Africa drive revenue growth

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered 1QFY22 earnings marginally below our expectation. Robust growth in Domestic Formulation (DF) / Branded Generics (Africa) was offset by moderate growth in US / Branded Generics (Asia) and enhanced opex towards marketing and promotional activities. AJP is on track to outperform in the Branded Generics segment across DF/Asia/Africa and build a product pipeline for the US market. We tweak our estimates for FY22E/FY23E, factoring in a) a better outlook for the Pain Management, Opthal, and Derma therapies in the DF segment,...

Ajanta Pharma Ltd. has gained 27.48% in the last 1 Year

Ajanta Pharma Ltd.

30 Jul 2021

2654.25

1.06%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations constitute 30% of the total consolidated turnover and is segregated into branded formulations & institutional business Asia accounts for ~35% of export formulations, Africa 33% & US 32%. The...

Ajanta Pharma Ltd. is trading below its 50 day SMA of 2673.4

Ajanta Pharma Ltd.

03 May 2021

2654.25

1.06%

Ajanta Pharma (BUY): Another good quarter

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) reported strong Q4FY21 revenue/EBITDA growth of 11%/56% YoY to Rs 7.6bn/Rs 2.6bn, surpassing consensus estimates by 3%/23%.

Ajanta Pharma Ltd. has gained 27.48% in the last 1 Year

Ajanta Pharma Ltd.

01 May 2021

2654.25

1.06%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

ICICI Securities Limited

Q4 revenues grew 11.0% YoY to | 757 crore. Domestic sales grew 23.2% to | 218 crore whereas emerging markets (branded) de-grew 10.5% YoY to | 273 crore amid logistical challenges in Asia and Africa. US sales grew 21% to | 173 crore. Africa tender business grew 86% YoY to | 80 crore. EBITDA margins improved significantly to 34.3% (vs. 22.2% in Q4FY20) amid better gross margins and lower other expenditure. EBITDA grew 71.4% YoY to | 259 crore. PAT grew 21% YoY to | 159 crore. Delta vis--vis EBITDA was...

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

03 Feb 2021

2654.25

1.06%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Q3 results were a beat on all fronts on the back of strong growth in branded generic sales in Emerging markets and India along with better gross margin performance. While the management expects subdued domestic growth in FY21 due to Covid-19, it expects high single digit growth for branded business in Asia, Africa (India, Asia, Africa- ~70% of sales) along with ~20% growth for US. On margins front, change in product mix (higher US revenues) notwithstanding, the management expects ~200-250 bps improvement in FY21, going ahead, with improving operating leverage and...

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

02 Feb 2021

2654.25

1.06%

Branded Generics drives earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered higher than expected earnings, led by superior growth in the Branded Generics segment. This was further supported by a lower tax rate in 3QFY21. While the pace of ANDA filing has moderated in 9MFY21 due to COVID-related disruptions, it would improve with the easing of lockdown restrictions. We have raised our FY21E/FY22/FY23E estimates by 7.4%/7.1%/6.5% to factor in: a) recovery in DF/Asia/Africa, b) robust ANDA pipeline, and c) improved capacity utilization. We continue to value AJP at 23x 12 months...

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

02 Feb 2021

2654.25

1.06%

Ajanta Pharma (BUY): Another good quarter; resilient outlook to drive stock upside

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) reported yet another excellent quarter with Q3 revenue/ EBITDA growth of 15%/30% YoY to Rs 7.5bn/Rs 2.4bn, surpassing our estimates by 11%/14%.

Ajanta Pharma Ltd. is trading above its 30 day SMA of 2589.9

Ajanta Pharma Ltd.

05 Nov 2020

2654.25

1.06%

Ajanta Pharma

Accumulate: Ajanta Pharma Ltd.

Dolat Capital

Ajanta Pharma reported stellar Q2 beating our estimates on the operating performance. Top-line grew 8% YoY, in-line with our estimate, driven by US and branded Africa business. Other geographies including India were muted. However, lower opex aided margins at 38.3% (up 490 bps QoQ and 1,070 bps YoY), way higher than our estimates. While the same is expected to taper as activities resume in subsequent quarters,...